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Junya Kanda,1 David A. Rizzieri,1 Cristina Gasparetto,1 Gwynn D. Long,1
John P. Chute,1 Keith M. Sullivan,1 Ashley Morris,1 Clayton A. Smith,3 Donna E. Hogge,3
Janet Nitta,3 Kevin Song,3 Donna Niedzwiecki,2 Nelson J. Chao,1 Mitchell E. Horwitz1High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched
umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective
trial of dual UCB transplantation using modified myeloablation consisting of total-body irradiation (TBI;
1350 cGy) and fludarabine (Flu) (160 mg/m2). Twenty-seven patients (median age, 33 years; range: 20-58
years) with hematologic malignancies were enrolled. The median combined cryopreserved total nucleated
cell (TNC) dose was 4.3  107/kg (range: 3.2-7.7  107/kg). The cumulative incidences of neutrophil
($500/mL) and platelet ($50,000/mL) engraftment were 80% (95% confidence interval [CI], 58%-91%) and
68% (95% CI, 46%-83%), respectively. Among engrafted patients, a single cord blood unit was predominant
by 100 days posttransplantation. A higher cryopreserved and infused TNC dose and infused CD31 cell dose
were significant factors associated with the predominant UCB unit (P 5 .032, .020, and .042, respectively).
TRM and relapse rates at 2 years were 28% (95% CI, 12%-47%) and 20% (95% CI, 7%-37%), respectively.
Cumulative incidences of grades II–IV and grades III–IV acute graft-versus-host disease (aGVHD) were
37% (95% CI, 20%-55%) and 11% (95% CI, 3%-26%), respectively, and that of chronic GVHD was 31%
(95% CI, 15%-49%). With a median follow-up of 23 months, overall survival and disease-free survival
rates at 2 years were 58% (95% CI, 34%-75%) and 52% (95% CI, 29%-70%), respectively. This study supports
the use of TBI 1350 cGy/Flu as an alternative to conventional myeloablative conditioning for dual UCB
transplantation.
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6/j.bbmt.2010.09.009(HSC) for pediatric and adult patients in need of
allogeneic stem cell transplantation [1-12]. However,
the high incidence of treatment-related mortality
(TRM) and graft failure have historically been significant
obstacles to wider application of myeloablative UCB
transplantation for adult patients [6-10]. In an early
multicenter retrospective study comparing outcomes of
myeloablative UCB transplantation to unrelated donor
transplantation, the neutrophil engraftment rate was
lower (\70%) and TRM was higher (63%, 95 of 150
patients) in the UCB transplantation cohort [7].
Multiple strategies have been employed to reduce
TRM associated with allogeneic stem cell transplanta-
tion. Although nonmyeloablative conditioning regi-
mens have been used in UCB transplantation as well
as in related or unrelated donor transplantation to
reduce TRM [13-17], patients with high-risk hemato-
logic malignancies would be expected to have an
increased risk of disease relapse following this
approach [18,19]. Therefore, there is critical need for867
868 Biol Blood Marrow Transplant 17:867-874, 2011J. Kanda et al.additional myeloablative conditioning regimens that
can exert potent antitumor activity and sufficient
immunosuppression to facilitate mismatched unrelated
cord blood engraftment, but are less toxic than
conventional myeloablative conditioning regimens
such as total-body irradiation (TBI), fludarabine (Flu),
and cyclophosphamide [20].
Here, we report the results from a consecutive co-
hort of patients who received dual UCB transplanta-
tion after conditioning with myeloablative TBI (1350
cGy) and Flu (160 mg/m2).METHODS
Inclusion Criteria
The inclusion criteria were as follows: (1) patients
aged between 14 years and 65 years; (2) patients with
high-risk lymphoblastic leukemia (ALL) (Philadelphia
chromosome positive) or acute myelogenous leukemia
(AML) (complex cytogenetic abnormality or antecedent
hematologic malignancy) in first complete remission
(CR1), or second or higher complete remission
($CR2); (3) patients with chronic myelogenous leuke-
mia (CML) in chronic phaseor acceleratedphase; (4) pa-
tients with myelodysplastic syndrome (MDS) with an
International Prognostic Scoring System risk category
of INT-1 or greater; (5) patients with non-Hodgkin
lymphoma (NHL) or Hodgkin lymphoma (HL) with
high-risk disease in CR1, $CR2, or first partial remis-
sion, or those with chemotherapy-resistant relapse; (6)
patients with an Eastern Cooperative Oncology Group
performance status# 2; (7) patientswith adequateorgan
function (creatinine,\2.0 mg/dL; aspartate aminotran-
saminases and alanine aminotransferase,\4  normal
value; bilirubin,\2.0 mg/dL; forced vital capacity and
forced expiratory volume in 1 second values, .50% of
the value predicted for age; carbon monoxide diffusing
capacity, .50% of the predicted value; ejection
fraction, .45%); (8) patients without a 6/6 or a 5/6
HLA-A, -B, or -DR antigen-matched related donor; and
(9) patients without an 8/8 HLA-A, -B, -C, and -DRB1
allele-matched unrelated donor by high-resolution
typing. CR of leukemia was defined as the absence of
any residual disease confirmed by morphology and flow
cytometry,whereasCRof lymphomawasdefined accord-
ing to the response criteria proposed byCheson et al. [21].
The studywas approvedby the institutional reviewboards
of the Duke University School of Medicine and the Uni-
versity of British Columbia. Written informed consent
was obtained from all patients prior to transplantation.Treatment Plan
The conditioning regimen consisted of TBI 150
cGy twice a day, total 9 fractions (days 29 to 25),
and Flu (Berlex Laboratories, Wayne, NJ, USA) 40mg/m2/day i.v.  4 days (days 25 to 22). The dose
to the lungs was attenuated (range: 8-10 Gy based on
degree of pulmonary dysfunction) in all patients using
the arms and brass compensators. Patients received 2
partially matched UCB grafts that were at least 4 of 6
HLA-matched with the recipient and 3 of 6 HLA-
matched between grafts (low-resolution A, B, high-
resolution DRB1). Each red cell–depleted graft
contained a minimum cryopreserved total nucleated
cell (TNC) dose of 1.5  107/kg, and each red cell–
containing unit contained a minimum cryopreserved
TNC dose of 2.0  107/kg. UCB units were thawed
and washed before transplantation using the methods
described by Rubinstein et al. [22], and 2 cord blood
units were infused sequentially with an arbitrary order
and no mandatory time interval. The colony-forming
unit (CFU) content (CFU-GM, CFU-GEMM, and
BFU-E), number of CD31 and CD341 cells, and
TNC count were determined for each washed cord
blood unit. Graft-versus-host disease (GVHD) pro-
phylaxis consisted of tacrolimus dosed to achieve
serum levels of 10-20 ng/mL for at least 6 months
and mycophenolate mofetil (MMF) 1000 mg twice
daily until at least 60 days following transplantation.
Granulocyte colony-stimulating factor was adminis-
tered until the neutrophil count exceeded 1000/mm3.
Voriconazole, acyclovir, and ciprofloxacin were given
as anti-infective prophylaxis for at least 3 months. To-
tal parenteral nutrition (TPN) was started when calo-
ric intake of patients was negligible. For the 24 patients
treated at Duke UniversityMedical Center, donor chi-
merismwas sequentially determined using quantitative
PCR amplification of informative microsatellites on
DNA isolated from CD31 and CD151 peripheral
blood or bone marrow cells.Statistical Analysis
The primary endpoint for this trial was donor stem
cell engraftment. The secondary endpoints were (1)
platelet engraftment; incidence of (2) acute and chronic
GVHD (aGVHD, cGVHD); (3) TRM; (4) relapse; and
(5) disease-free (DFS) and overall survival (OS). TPN
usage was also evaluated as a post hoc analysis. Day of
donor stem cell engraftment was defined as the first of
3 consecutive days achieving a neutrophil count of
$500/mLon or before transplant day 50.Day of platelet
engraftmentwas defined as thefirst of 3 consecutive days
achieving a platelet count of$20,000/mL and$50,000/
mL without platelet transfusion support on or before
transplant day 100. Patients with early death or relapse
without engraftment before day 21 were excluded
from the engraftment analysis. Day to TPN usage was
measured from the first day of conditioning to the first
dayofTPNrequirementbefore transplantday30.Acute
GVHD or cGVHD was characterized using standard
criteria [23,24]. DFS was measured from the day of
Table 1. Patient Characteristics for the 27 Recipients of Dual
Umbilical Cord Blood Transplantation
Characteristics n 5 27
Age (years), median (range) 33 (20-58)
Sex
Male 11 (41%)
Female 16 (59%)
Weight (kg), median (range) 74.7 (37-112)
Acute myelogenous leukemia 15 (56%)
CR1 1
CR2 14
Myelodysplastic syndrome 3 (11%)
RA 1
RAEB-1 1
RAEB-2 1
Chronic myelogenous leukemia
CP 1 (4%)
Acute lymphoblastic leukemia 5 (19%)
CR1 2
CR2 3
Non-Hodgkin lymphoma 3 (11%)
CR1 1
CR2 1
Relapse 1
CMV serostatus
Positive 17 (63%)
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death from any cause. To eliminate the effects of
competing risk, cumulative incidence was assessed
using methods described elsewhere [25]. In the analysis
of the cumulative incidence of neutrophil and platelet
engraftment, a competing event was defined as relapse
or death without an event of interest, whereas in the
analysis of relapse, aGVHDand cGVHD, andTPNus-
age, a competing event was defined as death without an
event of interest.Relapsewas definedas a competing risk
in the analysis ofTRM.DFS andOSwere estimated us-
ing the Kaplan-Meier method. We defined a predomi-
nant UCB unit as sustained $70% myeloid and
lymphoid chimerism after transplantation. The Wil-
coxon signed rank test was used to evaluate the effect
of cell dose and HLA compatibility on engraftment of
a predominant single cord unit. All tests were 2-sided,
and a P-value of \0.05 was considered to indicate
statistical significance. All statistical analyses were per-
formed using Stata version 11 (Stata Corp., College
Station, TX, USA).Negative 8 (30%)
Indeterminate 2 (7%)
CR indicates complete remission; RA, refractory anemia; RAEB, refractory
anemia with excessive blasts; CP, chronic phase; CMV, cytomegalovirus.
Data are counts of individuals unless specified otherwise.RESULTS
Patients and Graft Characteristics
A total of 27 patients with a median age of 33 years
(range: 20-58 years) and body weight of 74.7 kg (range:
37-112 kg) were treated on study between April 2006
and January 2010. Pretransplant disease characteristics
are shown in Table 1. The UCB graft characteristics
are shown in Table 2. The combined cryopreserved
and infused TNC counts of the 2 UCB units were
4.3  107/kg (range: 3.2-7.7  107/kg) and 3.8 
107/kg (2.6-6.0  107/kg), respectively. Seventy-four
percent of patients received 1 4/6 HLA-A, -B, and
-DRB1 matched unit and 1 4/6 or 5/6 matched unit.Engraftment
Neutrophil engraftment was achieved in 20 pa-
tients at a median of 24 days following transplantation
(range: 13-45 days). Two patients were excluded from
the engraftment analysis; 1 patient with AML in CR2
relapsed at day 14 after transplantation and died at
day 38 because of disease progression. The other pa-
tient died day 20 after transplantation because of mul-
tiorgan failure arising from cardiovascular collapse.
The cumulative incidence of neutrophil engraftment
at day 50 was 80% (95% confidence interval [CI],
58%-91%) for the 25 evaluable patients (Figure 1).
Three patients experienced primary graft failure, and
hematopoiesis was restored in 2 patients with either
autologous (n 5 1) or haploidentical allogeneic (n 5
1) hematopoietic stem cells. Platelet engraftment of
$20,000/mL was achieved in 19 patients in a median
of 37 days (range: 20-66 days), and $50,000/mL in17 patients in a median of 52 days (range: 33-78
days). The cumulative incidences of platelet engraft-
ment of $20,000/mL and $50,000/mL by day 100
were 76% (95% CI, 54%-88%) and 68% (95% CI,
46%-83%), respectively (Figure 1).
A comparison of the cryopreserved and infused
TNC dose, infused CD341 and CD31 cell count, and
CFU content in the dominant and nondominant units
is shown inFigure 2.Ahigher cryopreserved and infused
TNC and infused CD31 cell dose was associated with
establishment of the predominant UCB unit (cryopre-
served TNC, P 5 .032; infused TNC, P 5 .020;
CD31, P 5 .042) (Figure 2). There was no association
between the degree ofHLA compatibility and establish-
ment of a predominant UCB unit (P5 .206).GVHD
Acute GVHD grades II and III occurred in 7 and 3
patients, respectively. No patient developed grade IV
aGVHD. The cumulative incidences of grades II-IV
and grades III-IV aGVHD were 37% (95% CI,
20%-55%) and 11% (95% CI, 3%-26%), respectively
(Figure 3). Chronic GVHD occurred in 8 patients,
with a cumulative incidence of 31% (95% CI, 15%-
49%). There was no death attributable to aGVHD
or cGVHD. All but 1 episode of aGVHD occurred
prior to day 60, when mycophenolate mofetil was
scheduled to be discontinued.
Table 2. Graft Characteristics for the 27 Recipients of Dual
Umbilical Cord Blood Transplantation
Characteristics
Cryopreserved TNC, 107/kg,
median (range) (n 5 27)*
4.3 (3.2-7.7)
Infused TNC,107/kg, median (range)
(n 5 26)*
3.8 (2.6-6.0)
Infused CD34+, 105/kg, median
(range) (n 5 26)*
1.2 (0.3-4.9)
Infused CD3+, 106/kg, median
(range) (n 5 24)*
6.9 (3.6-11.6)
Infused CFU, 104/kg, median (range)
(n 5 27)*
14.3 (0.0-68.0)
HLA matching†
6/6 + 6/6, n (%) 1 (4)
5/6 + 6/6, n (%) 4 (15)
5/6 + 5/6, n (%) 2 (7)
4/6 + 5/6, n (%) 10 (37)
4/6 + 4/6, n (%) 10 (37)
TNC indicates total nucleated cell; CFU, colony-forming unit.
*Values reflect combined umbilical cord blood graft.
†HLA matching was expressed as the degree of matching between
recipient and each umbilical cord blood unit for HLA-A, HLA-B (low-
resolution typing), and HLA-DRB1 (high-resolution typing).
Figure 1. Cumulative incidence of (A) neutrophil and (B) platelet
engraftment of 50,000/mL.
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Weevaluated the cumulative incidenceof posttrans-
plant TPN usage as a surrogate marker of regimen-
related toxicity. The cumulative incidence of TPN
usage was 56% (95% CI, 35%-72%) at day 30.
Survival, TRM, and Relapse
With amedian follow-up of 23months (range: 3.6-
50.4months) among survivors, the 2-year OS andDFS
rates were 58% (95% CI, 34%-75%) and 52% (95%
CI, 29%-70%), respectively (Figure 4). Six patients
died within 100 days following transplantation because
of fungal infection (n5 1), diffuse alveolar hemorrhage
(n5 2), disease progression (n5 1), multiorgan failure
(n5 1), and graft failure (n5 1), whereas 4 patients died
after 100 days posttransplant because of disease pro-
gression (n 5 2), viral infection (n 5 1), and unknown
reason (n 5 1). At time of last follow-up, 3 patients
were alive with disease. The cumulative incidence of
TRM was 19% (95% CI, 7%-35%) at 180 days and
28% (95%CI, 12%-47%) at 2 years (Figure 4).The cu-
mulative incidence of relapse was 20% (95% CI, 7%-
37%) at 2 years (Figure 4). Among 7 patients aged
$50 years old, 6 patients are alive with a median
follow-up of 24 months (range: 3.6-35.0 months) and
1 patient died because of disease progression at day
402. One of 8 patients with lymphoid malignancies re-
lapsed, whereas 5 of 19 patients with myeloid malig-
nancies relapsed.
Myeloid and Lymphoid Chimerism
The predominant unit provided a median of 90%
donor myeloid and lymphoid chimerism at 1 month
following transplantation. Myeloid chimerism of thenondominant unit was still detectable at 12 months
following transplantation in 2 patients (Figure 5).
This has remained stable with nearly 2 years of
follow-up in both patients.DISCUSSION
Toreduce regimen-related toxicity butmaintain an-
titumor activity in UCB transplantation, we combined
a myeloablative dose of TBI with Flu instead of the
more commonly used TBI/Flu/cyclophosphamide
combination. With this myeloablative regimen, the
cumulative incidence of neutrophil engraftment was
80% with a median of 24 days, which is comparable to
that reported in previousmulticenter retrospective stud-
ies analyzing the outcomes ofmyeloablativeUCB trans-
plantation [7-10]. This engraftment rate is inferior to
what has been reported in adult dual cord blood
transplantation studies from Japan [26,27]. The reason
for this difference is unclear but may be attributable to
the genetic homogeneity of the Japanese population
[28]. The Minnesota group reported the largest series
of patients who received dual UCB transplantation after
myeloablative conditioning consisting of TBI/Flu/cy-
clophosphamide [29]. For 93 patients who received
dualUCBtransplantationwith this approach, the cumu-
lative incidences of neutrophil and platelet engraftment
Figure 2. Dot plots showing the impact of total nucleated cell dose, CD341 and CD31 cell dose, and CFU content on establishment of the predom-
inant unit and nondominant units for each patient. (A) Cryopreserved total nucleated cell dose (n5 20), median predominant unit 2.5 107/kg (range:
1.7-3.6 107/kg), median nondominant unit, 1.8 107/kg (range: 1.2-4.2 107/kg). (B) Infused total nucleated cell count (n5 19), median dominant unit
2.1 107/kg (range: 1.2-3.6 107/kg), median nondominant unit, 1.5 107/kg (range: 1.0-3.1 107/kg). (C) Infused CD341 cell dose (n5 20), median
dominant unit 0.7  105/kg (range: 0.2-1.6  105/kg), median nondominant unit 0.5  105/kg (range: 0.1-2.5  105/kg). (D) CD31 cell count (n 5 17),
median dominant unit 3.5  106/kg (range: 2.2-7.9 106/kg), median nondominant unit 3.4 106/kg (range: 1.3-5.1 106/kg). (E) Colony-forming unit
content (n 5 20), median dominant unit 6.5  104/kg (range: 0.3-28.7  104/kg), median nondominant unit 4.5  104/kg (range: 0.0-42.6  104/kg).
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which is slightly higher than the neutrophil engraftment
in our approach (80%) but slightly lower with respect to
platelet engraftment (68%). Although improving toler-
abilityof thepreparative regimen, it is possible that elim-
ination of cyclophosphamide negatively impacted the
engraftment rate. Larger studies are needed to deter-
mine whether the observed differences in engraftment
are significant.
It is difficult to compare regimen toxicity and toler-
ability because of the lack of objective methods for
measurement. We hypothesized that the elimination
of high-dose cyclophosphamide from thismyeloablative
preparative regimenwould improve tolerability in terms
of severity of mucositis, and a reduction inTRM.Using
our conditioning regimen, we obtained a TRM rate of
19% at 6 months and 28% at 2 years, which is lower
than in the earlier reports of myeloablative UCB
transplantation (40%-50% at 2 years) [8,10] and
comparable to other reports of UCB transplantation
after reduced-intensity conditioning (RIC) [13-16].
Brunstein et al. [14] reported a TRM rate of 19% at 6
months and 26% at 3 years in dual UCB transplantation
afterRICusingFlu (200mg/m2), cyclophosphamide (50
mg/kg), and low-doseTBI (200 cGy). Although a recent
report of dual UCB transplantation after myeloablativeconditioning with TBI/Flu/cyclophosphamide showed
a low TRM rate of 29% at 1 year [29], the median age
of this cohort (median, 24 years; range: 9-57 years) was
lower than that of our cohort (median, 33 years; range:
20-58 years), thus making it difficult to compare the
results. We observed no treatment-related death in the
7 patients over age 50 years. Larger studies will be
needed toconfirmwhat appears tobe a favorable toxicity
profile for a select group of older patients. One of the
weaknesses of the study is that we did not objectively
measure the severity ofmucositis. As a surrogate formu-
cositis measurement, we evaluated the incidence of
TPNusageafter transplantation,andfoundacumulative
incidence of TPN usage of just 56%. This suggests that
treatment-related toxicity, including mucosal damage,
may be milder than what is expected following conven-
tional myeloablative regimens, where TPN usage
typically approaches 100%. However, the criteria for
initiating TPN varies across transplant centers, and
the rate of TPN usage and degree of mucosal damage
might be affected not only by the conditioning regimen,
but also by the use of MMF instead of methotrexate for
GVHD prophylaxis. Therefore, definitive conclusions
cannot be drawn from this finding.
Use of a myeloablative dose of TBI (1350 cGy) with
Flu retains myeloablative properties based on the fact
Figure 4. (A) Overall and (B) disease-free survival, (C) treatment-
related mortality, and (D) relapse rates.
Figure 3. Cumulative incidence of (A) acute and (B) chronic GVHD.
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topoietic reconstitution, and assuresmaintenance of po-
tent antitumor activity. The relapse rate in our study
(20% at 2 years) is comparable to, or better than previ-
ous reports of UCB transplantation after conventional
or RIC [7,8,10,14], although the heterogeneity of
patient diagnoses limits the broad applicability of this
finding. Brunstein et al. [14] reported a relapse rate of
31% at 3 years after UCB transplantation using RIC
for patients with a similarly diverse spectrum of hema-
tologic malignancies [14]. Because of the comparable
TRM and low relapse rate, we obtained respectable
2-year OS (58%) and relapse-free survival (RFS)
(52%) rates for patients with hematologic diseases at
a high risk of relapse.
After dualUCB transplantation,mixedUCB chime-
rism has been observed for a few weeks or months, but
converts to complete single UCB chimerism by 1 year
in almost all patients [16,20]. We report here the
phenomenon of stable dual cord blood chimerism
observed in 2 of our study patients. Definitive graft
characteristics that predict for the predominant unit are
unknown. A higher CD31 dose has been associated
with the predominant unit in 2 prior studies [20,30].
The current study confirms this observation. Prior
reports have also implicated the order of cord blood
graft infusion, CD341 cell viability, and the presence
Figure 5. Sequential change of myeloid chimerism for 2 patients (A and
B) who had long-lasting dual cord blood chimerism.
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effector CD81 T cells, as the driving force behind the
emergence of a predominant graft [13,30,31]. We
could not verify the importance of CD341 cell viability
in this study because we performed a postthaw wash
of the UCB units, resulting in high ($90%) viability of
all cell types (data not shown). In contrast to other
reports of both myeloablative and nonmyeloablative
dual cord blood transplantation [14,20], we found
that the graft with the higher TNC content was more
likely to become the predominant unit. However, there
was a weak correlation between CD3 content and
cryopreserved (R 5 .52, P\ .01) or infused (R 5 .48,
P \ .01) TNC dose. Given this weak but significant
correlation, we cannot determine which of these factors
is the most important determinant for engraftment.
Tomaintainconsistencywith the statisticalmethods
employed by comparable UCB transplant studies
[14,20,29,32], we excluded 2 patients with very early
toxic death and relapse from the cumulative incidence
calculations. Although this deviates from the classical
methods for calculation of cumulative incidence [33],
we believe this to be a rational approach because these
patients do not reflect the effect of this regimen on
engraftment. This methodologic difference should be
considered when comparing the engraftment rates be-
tween studies. In the early multicenter retrospective
study of myeloablative UCB transplantation, the neu-
trophil engraftment was 70%-75% in the analysis for
all patients including early toxic death cases [7,8]. If
the 2 patients with early toxic death were included inour analysis, neutrophil engraftment rate would be
74% (95% CI, 53%-87%).
In conclusion, we find that the modified myeloabla-
tive regimen of TBI (1350 cGy)/Flu provides stem cell
engraftment rates comparable to more conventional
myeloablative regimens. In contrast to other reports,
we found that graft size predicts for the predominant
UCB unit. This study supports the use of TBI 1350
cGy/Flu as an alternative to conventional myeloablative
conditioning for dual UCB transplantation and pro-
vides justification for larger studies.ACKNOWLEDGMENTS
The study investigators wish to thank the nurse
practitioners, physician’s assistants, ward and clinic
nurses, and staff of the Duke Adult Stem Cell Trans-
plant Program for their outstanding care of the patients
described in this report. J.K. is a Research Fellow of the
Japan Society for the Promotion of Science.
Financial disclosure: N.C. and M.H. have relevant
financial relationships as follows: Genzyme, research
funding (N.C), and Genzyme, honoraria and research
funding (M.H.). The other authors have no relevant
financial relationship to disclose.REFERENCES
1. Kurtzberg J, Laughlin M, GrahamML, et al. Placental blood as
a source of hematopoietic stem cells for transplantation into
unrelated recipients. N Engl J Med. 1996;335:157-166.
2. Wagner JE, Rosenthal J, Sweetman R, et al. Successful trans-
plantation of HLA-matched and HLA-mismatched umbilical
cord blood from unrelated donors: analysis of engraftment and
acute graft-versus-host disease. Blood. 1996;88:795-802.
3. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of
cord-blood transplantation from related and unrelated donors.
Eurocord Transplant Group and the European Blood and Mar-
row Transplantation Group. N Engl J Med. 1997;337:373-381.
4. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among
562 recipients of placental-blood transplants from unrelated
donors. N Engl J Med. 1998;339:1565-1577.
5. ChaoNJ, Koh LP, LongGD, et al. Adult recipients of umbilical
cord blood transplants after nonmyeloablative preparative regi-
mens. Biol Blood Marrow Transplant. 2004;10:569-575.
6. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical
cord blood transplantation in adult patients. Biol Blood Marrow
Transplant. 2003;9:772-780.
7. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantation of cord blood or bone marrow from unrelated
donors in adults with leukemia. N Engl J Med. 2004;351:
2265-2275.
8. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-
cord blood or bone marrow from unrelated donors in adults
with acute leukemia. N Engl J Med. 2004;351:2276-2285.
9. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood
transplantation in adults: results of the prospective Cord Blood
Transplantation (COBLT). Biol Blood Marrow Transplant.
2005;11:149-160.
10. Arcese W, Rocha V, Labopin M, et al. Unrelated cord blood
transplants in adults with hematologic malignancies. Haemato-
logica. 2006;91:223-230.
874 Biol Blood Marrow Transplant 17:867-874, 2011J. Kanda et al.11. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative
analysis of unrelated bone marrow transplantation and cord
blood transplantation for adult patients with hematologicmalig-
nancies. Blood. 2004;104:3813-3820.
12. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific
analyses of unrelated cord blood transplantation compared
with unrelated bone marrow transplantation in adult patients
with acute leukemia. Blood. 2009;113:1631-1638.
13. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated
reduced-intensity umbilical cord blood transplantation in
adults. Biol Blood Marrow Transplant. 2007;13:82-89.
14. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord
blood transplantation after nonmyeloablative conditioning:
impact on transplantation outcomes in 110 adults with hemato-
logic disease. Blood. 2007;110:3064-3070.
15. Miyakoshi S, Yuji K, KamiM, et al. Successful engraftment after
reduced-intensity umbilical cord blood transplantation for adult
patients with advanced hematological diseases. Clin Cancer Res.
2004;10:3586-3592.
16. Cutler C, Ballen K. Reduced-intensity conditioning and
umbilical cord blood transplantation in adults. Bone Marrow
Transplant. 2009;44:667-671.
17. Miyakoshi S, Kami M, Tanimoto T, et al. Tacrolimus as pro-
phylaxis for acute graft-versus-host disease in reduced intensity
cord blood transplantation for adult patients with advanced
hematologic diseases. Transplantation. 2007;84:316-322.
18. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative out-
come of reduced intensity and myeloablative conditioning regi-
men in HLA identical sibling allogeneic haematopoietic stem
cell transplantation for patients older than 50 years of age with
acute myeloblastic leukaemia: a retrospective survey from the
Acute Leukemia Working Party (ALWP) of the European
group for Blood and Marrow Transplantation (EBMT).
Leukemia. 2005;19:2304-2312.
19. Ringden O, Labopin M, Ehninger G, et al. Reduced intensity
conditioning compared with myeloablative conditioning using
unrelated donor transplants in patients with acute myeloid
leukemia. J Clin Oncol. 2009;27:4570-4577.
20. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2
partially HLA-matched umbilical cord blood units to enhance
engraftment in adults with hematologic malignancy. Blood.
2005;105:1343-1347.
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response cri-
teria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.22. Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and
cryopreservation of placental/umbilical cord blood for unrelated
bone marrow reconstitution. Proc Natl Acad Sci U S A. 1995;92:
10119-10122.
23. PrzepiorkaD,WeisdorfD,Martin P, et al. 1994Consensus con-
ference on acuteGVHDgrading.BoneMarrow Transplant. 1995;
15:825-828.
24. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow trans-
plantation. Semin Hematol. 1991;28:250-259.
25. Gooley TA, LeisenringW, Crowley J, Storer BE. Estimation of
failure probabilities in the presence of competing risks: new
representations of old estimators. Stat Med. 1999;18:695-706.
26. Ooi J, Takahashi S, Tomonari A, et al. Unrelated cord blood
transplantation after myeloablative conditioning in adults with
acute myelogenous leukemia. Biol Blood Marrow Transplant.
2008;14:1341-1347.
27. Ooi J, Takahashi S, Tomonari A, et al. Unrelated cord blood
transplantation after myeloablative conditioning in adults with
ALL. Bone Marrow Transplant. 2009;43:455-459.
28. Oh H, Loberiza FR Jr., Zhang MJ, et al. Comparison of graft-
versus-host-disease and survival after HLA-identical sibling
bone marrow transplantation in ethnic populations. Blood.
2005;105:1408-1416.
29. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after
umbilical cord blood transplantation: enhanced graft-versus-
leukemia effect in recipients of 2 units. Blood. 2009;114:
4293-4299.
30. Scaradavou A, Smith KM,Hawke R, et al. Cord blood units with
low CD341 cell viability have a low probability of engraftment
after double unit transplantation. Biol Blood Marrow Transplant.
2010;16:500-508.
31. Gutman JA, Turtle CJ, Manley TJ, et al. Single-unit dominance
after double-unit umbilical cord blood transplantation coincides
with a specific CD81 T-cell response against the nonengrafted
unit. Blood. 2010;115:757-765.
32. MacMillan ML,Weisdorf DJ, Brunstein CG, et al. Acute graft-
versus-host disease after unrelated donor umbilical cord blood
transplantation: analysis of risk factors. Blood. 2009;113:
2410-2415.
33. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods
for the analysis and presentation of the results of bone marrow
transplants. Part I: unadjusted analysis. Bone Marrow Transplant.
2001;28:909-915.
